NCT02676336已完成不适用
A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 31
- 试验地点
- 3
- 主要终点
- Change in self assessed cyclic breast discomfort
研究概览
简要总结
This is a randomized, double-blind, placebo controlled, multi-center study to evaluate the safety, tolerability and potential effects of dietary supplement Violet™ Iodine on breast health in women with cyclic breast discomfort and tenderness to eliminate the evaluation of effectiveness.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Healthy premenopausal females ≥ 18 years of age
- •BMI 20.0 - 29.9 kg/m2 (± 1 kg/m2)
- •Females of childbearing potential must agree to use a reliable and consistent method of birth control in the Investigator's opinion, excluding depot contraceptives and Explanon, and have a negative urine pregnancy test result. Hormonal contraceptives such as oral contraceptives, birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing) are all acceptable as long as the subject is on a stable dose and agrees not to change during the study period
- •No apparent health conditions that in the investigator's opinion would interfere with study participation, compliance or interpretation of endpoints or would not be in the best interest of the subject
- •Moderate to severe cyclic breast discomfort of at least 4 days per month (discomfort ≥4 on a 0-10 scale)
- •No known medical or psychological condition that in the investigator's opinion could interfere with study participation
- •Agrees to comply with all study related procedures and visits including access to a smartphone (Android or iOS) and ability to enter daily diary information via a smart phone app
- •Capable of reading and understanding study related materials (in English or French) and has given voluntary, written, informed consent to participate in the study
排除标准
- •Women who are pregnant, breast feeding, or planning to become pregnant during the course of the trial
- •Perimenopausal or irregular menstrual cycles
- •Women who have had an oophorectomy
- •Known thyroid condition or currently taking any thyroid medications
- •Prior bariatric surgery or other interventions or medications that might affect gastric pH
- •Use of iodine supplementation, Tamoxifen, Lupron, or Danazol, in the last 6 months
- •Clinically significant abnormal laboratory results at Screening
- •Breast implant surgeries that have not fully healed or have ongoing problems associated with the implant (i.e. seroma, infection etc.)
- •Planned elective surgeries to occur during participation in the study
- •Known allergy or sensitivity to study product ingredients (e.g. Iodine)
- •History of alcohol or drug abuse within the past year
- •Use of medicinal marijuana within the past year
- •Participation in a clinical research trial within 30 days prior to randomization or plans to participate in any other study during the next 11 months
- •Individuals who are cognitively impaired and/or who are unable to give informed consent
- •Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures, may confound interpretation of study outcome measures (such as another condition) or which may pose significant risk to the subject
研究组 & 干预措施
Violet™ Iodine
Active Comparator
3mg molecular iodine (I2) daily
干预措施: Violet™ Molecular Iodine (I2) (Dietary Supplement)
Placebo
Placebo Comparator
3mg placebo daily
干预措施: Placebo (Other)
Cross-over
Active Comparator
Subjects on placebo will be offered 3 months of active post-treatment
干预措施: Violet™ Molecular Iodine (I2) (Dietary Supplement)
结局指标
主要结局
Change in self assessed cyclic breast discomfort
时间窗: After 6 months of active treatment with molecular iodine (I2) compared to placebo
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary SyndromeAcute Coronary SyndromeNCT00548587Eisai Inc.600
已完成
2 期
A Study of PCSK9 Inhibitor AK102 in Patients With HypercholesterolemiaHypercholesterolemiaNCT04358432Akeso262
已完成
2 期
A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)Heterozygous Familial HypercholesterolemiaNCT04173793Akeso109
终止
2 期
Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe PruritusCholestatic PruritusNCT03995212Cara Therapeutics, Inc.14
已完成
3 期
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)Uremic PruritusNCT03422653Cara Therapeutics, Inc.378